{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.4","upperLimit":"53.1","value":"35.8"},{"groupId":"OG001","lowerLimit":"29.3","upperLimit":"72.0","value":"38.4"},{"groupId":"OG002","lowerLimit":"17.3","upperLimit":"63.3","value":"33.7"},{"groupId":"OG003","lowerLimit":"16.9","upperLimit":"64.3","value":"37.2"},{"groupId":"OG004","lowerLimit":"11.7","upperLimit":"355.0","value":"24.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"9"}],"units":"Participants"}],"description":"On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Apparent oral clearance (CL/F) was estimated using a non-compartmental method.","dispersionType":"Full Range","groups":[{"description":"Less-heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Stratum I, Dose Level 1 (50 mg/m2)"},{"description":"Less-heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Stratum I, Dose Level 2 (75 mg/m2)"},{"description":"Less-heavily pre-treated patients received oral palbociclib daily at 95 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Stratum I, Dose Level 3 (95 mg/m2)"},{"description":"Heavily pre-treated patients received oral palbociclib daily at 50 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Stratum II, Dose Level 1 (50 mg/m2)"},{"description":"Heavily pre-treated patients received oral palbociclib daily at 75 mg/m2/day for 21 days followed by a week rest (one course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Stratum II, Dose Level 2 (75mg/m2)"}],"paramType":"MEDIAN","populationDescription":"Patients with blood samples collected for pharmacokinetic studies on days 1-3 of course 1 were included.","reportingStatus":"POSTED","timeFrame":"Up to day 3","title":"Single Dose Apparent Oral Clearance (CL/F)","type":"PRIMARY","unitOfMeasure":"L/h/m^2"}